



Radiant Pharma Contact:
Kristine Szarkowitz
Director-Investor Relations
kszarkowitz@radiant-pharma.com
(Tel :) 206.310.5323

FOR IMMEDIATE RELEASE

RADIANT PHARMACEUTICALS CREATES MEDICAL ADVISORY BOARD; ADDS DIRECTOR OF ONCOLOGY TO LEAD EFFICACY EFFORTS FOR COMPANY'S ONKO-SURE™ IVD CANCER TEST

(TUSTIN, CA) April 26, 2010/Marketwire – Through its US-based subsidiary AMDL Diagnostics Inc., Radiant Pharmaceuticals Corporation (RPC) (NYSE - AMEX: [RPC](#) - [News](#)) announced it has established a cancer-specific medical advisory board with plans to secure an oncology expert as RPC's Director of Oncology. In this role, RPC's Director of Oncology will lead and oversee clinical studies to support product efficacy for RPC's Onko-Sure™ *in vitro* diagnostic (IVD) cancer test.

RPC expects these new functions will help RPC more aggressively accelerate market awareness and adoption of the Company's Onko-Sure IVD cancer test. Specific responsibilities include support for and guidance on RPC's global marketing strategy, product and healthcare advocacy programs and scheduled peer reviewed articles and white papers. The team will also support RPC's growing portfolio of strategic partners who provide substantial marketing resources to drive and increase Onko-Sure sales, both domestically and internationally.

According to Douglas MacLellan, Chairman and CEO of Radiant Pharmaceuticals, "It's important for the marketplace to understand the arduous and often time-challenging process of commercializing a successful IVD cancer test. RPC continues to make significant and productive progress in its efforts to commercialize Onko-Sure, and today's announcement demonstrates our continued commitment down this path."

RPC has achieved critical business and product milestones in support of the worldwide commercialization of Onko-Sure™ including the following:

- Secured regulatory and healthcare approvals from the US FDA, Health Canada, European Union, Indian government, Korean government, and Taiwanese government for Onko-Sure™ as a cancer monitoring or cancer screening test;
- Secured US GMP certification for RPC's Onko-Sure test kit manufacturing facility at the Company's Tustin California facilities;
- Signed long-term distribution agreements in at least 15 key world markets with the goal of securing at least 10 new partnerships in fiscal year 2010; and,

- Published new clinical data for Onko-Sure. RPC plans to continue publishing peer review articles, white papers, progress reports on current research studies and other related Onko-Sure materials on a scheduled basis for the remainder 2010 and beyond.

MacLellan continued, “In order to build Onko-Sure into a trusted brand, we believe our cancer test must have marketplace support from known contemporary oncology professionals who can advocate the value and use of our product to the broader universe of healthcare professionals and patients. The creation of a medical advisory board and Director of Oncology are the absolute right steps to take in order to establish increased awareness, loyalty to, and sales for RPC’s Onko-Sure.”

Onko-Sure is a simple, non-invasive, patent-pending and regulatory-approved *in vitro* diagnostic test for use as an aid in early detection of cancer. Onko-Sure enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer screen and cancer monitoring tool.

For additional information on Radiant Pharmaceuticals and its subsidiary AMDL Diagnostics Inc. visit the corporate website at www.Radiant-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at IR@Radiant-Pharma.com or 1.206.310.5323.

About Radiant Pharmaceuticals:

Headquartered in Tustin, California, Radiant Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and therapeutic products.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radiant Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

###